Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for CMV prevention in HSCT
NCT02137772Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of letermovir in cytomegalovirus infection (CMV), sponsored by Merck & Co.. Started Jun 2014; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02137772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02137772.